Insight Molecular Diagnostics Inc. — Director's Dealing 2017

Feb 22, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2017-02-17

Reporting Person: BROADWOOD PARTNERS, L.P. (10% Owner)
Reporting Person: BROADWOOD CAPITAL INC (10% Owner)
Reporting Person: BRADSHER NEAL C (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-02-17	Common Stock, no par value	X	425000	$3.25	Acquired	3056680	Direct
2017-02-17	Common Stock, no par value	X	0	$3.25	Acquired	3056680	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-17	Warrant to Purchase Common Stock	$3.25	X	425000	Disposed	2021-10-17	Common Stock (425000)	Direct
2017-02-17	Warrant to Purchase Common Stock	$3.25	X	0	Disposed	2021-10-17	Common Stock (0)	Indirect
2017-02-17	Warrant to Purchase Common Stock	$3.25	J	212500	Acquired	2022-02-17	Common Stock (212500)	Direct
2017-02-17	Warrant to Purchase Common Stock	$3.25	J	0	Acquired	2022-02-17	Common Stock (0)	Indirect

Footnotes

F1: These securities are owned by Broadwood Partners, L.P., which is a Reporting Person.

F2: The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. The Reporting Persons disclaim beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F3: These warrants are currently exercisable.

F4: These warrants were purchased as part of a unit, with each unit consisting of one share and one warrant (each warrant entitles the holder to purchase one share), at a price of $3.25 per unit.

F5: In consideration for the early exercise by Broadwood Partners, L.P. of 425,000 warrants on February 17, 2017, Broadwood Partners, L.P. received from the Issuer one new warrant with an exercise price of $3.25 for every two warrants that it exercised.